Verastem Inc. buy stratec
Start price
27.01.18
/
50%
€37.88
Target price
02.07.19
€162.36
Performance (%)
-60.57%
End price
02.07.19
€14.94
Summary
This prediction ended on 02.07.19 with a price of €14.94. The BUY prediction by stratec for Verastem Inc. performed very badly with a performance of -60.57%. stratec has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Verastem Inc. | 0.893% | 0.893% | 123.250% | -64.086% |
| iShares Core DAX® | -0.654% | 1.989% | 14.984% | 18.052% |
| iShares Nasdaq 100 | 0.903% | 5.664% | 36.140% | 58.351% |
| iShares Nikkei 225® | -0.740% | -1.363% | 10.792% | 6.321% |
| iShares S&P 500 | -0.013% | 3.020% | 28.126% | 48.476% |
Comments by stratec for this prediction
In the thread Verastem Inc. diskutieren
VSTM is focused on developing and commercializing therapeutics that improve outcomes for cancer patients.
Verastem's primary drug candidate is a compound called duvelisib which is in trials for a variety of indications.
On April 9th, the FDA accepted Verastem's marketing application seeking approval for duvelisib for the treatment of relapsed/reractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and accelerated approval for relapsed/refractory follicular lymphoma (NYSE:FL).
The comment has been deleted